1. Home
  2. QRVO vs COGT Comparison

QRVO vs COGT Comparison

Compare QRVO & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qorvo Inc.

QRVO

Qorvo Inc.

HOLD

Current Price

$87.32

Market Cap

8.2B

Sector

Technology

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$38.39

Market Cap

6.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QRVO
COGT
Founded
1957
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
6.6B
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
QRVO
COGT
Price
$87.32
$38.39
Analyst Decision
Hold
Strong Buy
Analyst Count
13
15
Target Price
$90.64
$36.21
AVG Volume (30 Days)
1.3M
2.7M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
524.14
N/A
EPS
3.62
N/A
Revenue
$3,678,517,000.00
$7,871,000.00
Revenue This Year
$0.81
N/A
Revenue Next Year
N/A
$1,733.58
P/E Ratio
$24.17
N/A
Revenue Growth
N/A
N/A
52 Week Low
$75.43
$8.80
52 Week High
$109.49
$43.73

Technical Indicators

Market Signals
Indicator
QRVO
COGT
Relative Strength Index (RSI) 36.52 70.58
Support Level $77.24 $37.54
Resistance Level $92.40 $40.62
Average True Range (ATR) 4.13 1.51
MACD -1.37 0.53
Stochastic Oscillator 3.40 81.96

Price Performance

Historical Comparison
QRVO
COGT

About QRVO Qorvo Inc.

Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of non-smartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: